Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) EBITDA: 2011-2023

Historic EBITDA for SELLAS Life Sciences Group (SLS) over the last 4 years, with Dec 2023 value amounting to -$8.2 million.

  • SELLAS Life Sciences Group's EBITDA rose 13.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 9.73%. This contributed to the annual value of -$37.9 million for FY2023, which is 9.73% up from last year.
  • Latest data reveals that SELLAS Life Sciences Group reported EBITDA of -$8.2 million as of Q4 2023, which was up 12.65% from -$9.4 million recorded in Q3 2023.
  • In the past 5 years, SELLAS Life Sciences Group's EBITDA ranged from a high of -$2.2 million in Q1 2021 and a low of -$16.7 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was -$8.8 million (2022), whereas its average is -$8.8 million.
  • Per our database at Business Quant, SELLAS Life Sciences Group's EBITDA skyrocketed by 44.76% in 2021 and then slumped by 645.43% in 2022.
  • Over the past 4 years, SELLAS Life Sciences Group's EBITDA (Quarterly) stood at -$4.2 million in 2020, then plummeted by 179.37% to -$11.6 million in 2021, then climbed by 18.70% to -$9.4 million in 2022, then increased by 13.43% to -$8.2 million in 2023.
  • Its EBITDA stands at -$8.2 million for Q4 2023, versus -$9.4 million for Q3 2023 and -$9.1 million for Q2 2023.